Scarica l'app Stockscreener
54.87
0.90%
0.49
Dopo l'orario di chiusura:
54.87
Precedente Chiudi:
$54.38
Aprire:
$54.82
Volume 24 ore:
1.99M
Relative Volume:
0.72
Capitalizzazione di mercato:
$10.62B
Reddito:
$2.83B
Utile/perdita netta:
$-1.02B
Rapporto P/E:
-9.9583
EPS:
-5.51
Flusso di cassa netto:
$194.14M
1 W Prestazione:
-2.51%
1M Prestazione:
+1.63%
6M Prestazione:
-12.15%
1 anno Prestazione:
+22.83%
Intervallo 1D:
$54.43
$55.78
Intervallo di 1 settimana:
$54.16
$56.73
Portata 52W:
$39.97
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Confronta EXAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
54.87 | 10.62B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
401.90 | 152.06B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.02 | 135.91B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
524.91 | 41.29B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.80 | 31.79B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
152.32 | 24.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio? - Yahoo Finance
Global Colorectal Cancer Screening and Diagnostics Market to Reach $46.1 Billion by 2029 - WV News
Corporate Wellness News from PRNEWSWIRE - Corporate Wellness Magazine
Epigenetics Market Anticipated to Achieve 11.8% CAGR - GlobeNewswire Inc.
Exact Sciences at William Blair Conference: Vision for Cancer Eradication - Investing.com
Transcript : Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08 - marketscreener.com
Exact Sciences (EXAS): Company Profile, Stock Price, News, Rankings - Fortune
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap - Business Wire
Exact Sciences Clears Technical Benchmark, Hitting 80-Plus RS Rating - inkl
Exact Sciences Announces Expanded Clinical Validation Of Oncodetect Test And Molecular Residual Disease Innovation Roadmap - marketscreener.com
Exact Sciences to present new positive data on Oncodetect in colorectal cancer - TipRanks
Exact Sciences (EXAS) Unveils Advanced MRD Test Data for Colorectal Cancer | EXAS Stock News - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Onc - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap | EXAS Stock News - GuruFocus
Exact Sciences management to meet with Oppenheimer - TipRanks
Exact Sciences to Participate in June Investor Conference | EXAS Stock News - GuruFocus
Exact Sciences to Participate in June Investor Conference - The Joplin Globe
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 2,099 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Highlights Innovations in Early Cancer Detection - GuruFocus
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025 - Business Wire
WisBusiness: the Show with Kevin Boggs of Medical College of Wisconsin - WisBusiness
Exact Sciences Corporation (EXAS) Slid on Fear of Competition - Insider Monkey
Comerica Bank Lowers Position in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
EXAS Q1 Earnings Call: Outperformance Driven by Commercial Execution, New Products, and Margin Expansion - Yahoo Finance
10 High PE Stocks Insiders Are Buying - Insider Monkey
Exact Sciences at Bank of America 2025 Healthcare Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years - AOL.com
Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Exact Sciences Earns 2025 Great Place To Work® Certification™ - Business Wire
Functional Genomics Market Top PlayersExact Sciences - openPR.com
Exact Sciences Announces First-Quarter 2025 Results - ADVFN
Exact Sciences (NASDAQ:EXAS) Price Target Raised to $72.00 - Defense World
Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report - Yahoo
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript - Insider Monkey
Exact Sciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp Reports Strong Start to 2025 - TipRanks
Exact Sciences (EXAS) Target Price Raised by Barclays to $75 | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Price Target Raised by RBC Capital | EXAS Stock News - GuruFocus
Exact Sciences: Q1 Earnings Snapshot - GMToday.com
Lobbying Update: $470,000 of EXACT SCIENCES lobbying was just disclosed - Nasdaq
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - Barchart.com
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday - Benzinga
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS S - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS Stock News - GuruFocus
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance - Benzinga
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analys - GuruFocus
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):